GRANULES Granules India Q4 FY25 results (Jan–Mar 2025) and concall
Granules India reported a mixed Q4 FY25, with modest revenue growth and strong margin expansion driven by a shift towards high-margin formulation products. The company is actively addressing a US FDA warning letter at its Gagillapur facility, which is expected to cause operational slowdowns for the next two quarters. Strategic initiatives include the acquisition of Senn Chemicals for peptide therapeutics, commissioning of Phase-1 and Phase-2 of the Genome Valley formulation facility, and expansion of its oncology and ADHD portfolios, positioning the company for future growth despite near-term
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 568 | 842 | 768 |
| EBITDA | 103 | 168 | 117 |
| Net profit | 41 | 90 | 94 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
